ArticleCancer science2023
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
Open access · goldAbstract read
In one paragraph
Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.British journal of haematology · 2026Article
- MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.Annals of hematology · 2026Observational
- The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.Bone marrow transplantation · 2026Article
- Review
- Metallothionein 1: the Achilles heel ofHaematologica · 2026Article
- Article
- A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts.Diagnostics (Basel, Switzerland) · 2025Review
- Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.Annals of hematology · 2025Article
- Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations.Blood cancer journal · 2025Article
- A significant correlation exists between CREBBP and CEBPA gene expression in de Novo adult acute myeloid leukemia.Scientific reports · 2025Article
- Allogeneic hematopoietic stem cell transplantation could overcome the poor prognosis of DNMT3AFrontiers of medicine · 2025Article
- Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.International journal of hematology · 2025Article
- Gene Mutation Characteristics and Prognostic Significance in Acute Myeloid Leukemia Patients From Northeast China.Human mutation · 2025Article
- DNMT3A-R882: a mutation with many paradoxes.Annals of hematology · 2024Review
- Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.Cancer medicine · 2024Article
- Prognostic impact ofTherapeutic advances in hematology · 2024Article
- A nomogram based on clinical features and molecular abnormalities for predicting the prognosis of patients with acute myeloid leukemia.Translational cancer research · 2023Article
- Genetic, Phenotypic, and Clinical Heterogeneity of NPM1-Mutant Acute Myeloid Leukemias.Biomedicines · 2023Review
- Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.Cancer science · 2023Article
- Analysis of the clinical characteristics and prognosis of adultOpen medicine (Warsaw, Poland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors at 20 institutions in 1 country.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5810-5433
Atsushi MarumoDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kaoru MoritaDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Takashi ToyaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-8910-0021
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-6704-3633
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0001-6130-1550
Shinichiro MoriHematology Department, St. Luke's International Hospital, Tokyo, Japan.
Atsushi SatakeFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-1216-4470
Toshimitsu UekiDepartment of Hematology, Nagano Red Cross Hospital, Nagano, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross, Kyoto Daini Hospital, Kyoto, Japan.
Yutaka KobayashiDepartment of Hematology, Japanese Red Cross, Kyoto Daini Hospital, Kyoto, Japan.
Eri KawataDepartment of Hematology, Panasonic Health Insurance Organization Matsushita Memorial Hospital, Osaka, Japan.
Kazutaka NakayamaDepartment of Hematology, Yokohama Minami Kyousai Hospital, Yokohama-shi, Japan.
Yuhei NagaoDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
Katsuhiro ShonoDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
Motoharu ShibusawaDepartment of Hematology, IMS group Shinmatsudo Central General Hospital, Chiba, Japan.
Jiro TadokoroDepartment of Hematology, IMS group Shinmatsudo Central General Hospital, Chiba, Japan.
Masao HagiharaDepartment of Hematology, Eiju General Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7143-4813
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.
Yasushi KubotaDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.ORCID https://orcid.org/0000-0003-1717-6208
Hisao NagoshiDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Saiko KurosawaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Sayuri MotomuraDepartment of Hematology, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6960-0800
Akiko HashimotoDepartment of Immunology and Hematology, Kobe City Nishi-Kobe Medical Center, Kobe, Japan.
Hideharu MutoDivision of Hematology Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Eriko SatoDepartment of Hematology, Juntendo University Nerima Hospital, Tokyo, Japan.
Masao OgataDepartment of Hematology, Oita University Hospital, Oita, Japan.
Kenjiro MitsuhashiDepartment of Hematology, Saitama Red Cross Hospital, Saitama, Japan.
Jun AndoDivision of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Haruko TashiroDepartment of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan.
Masahiro SakaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Shunsuke YuiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kunihito AraiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Tomoaki KitanoDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Miho MiyataDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Haruka AraiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Masayuki KandaDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Kako ItabashiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Nippon Medical School · JPJichi Medical University · JPTokyo Metropolitan Komagome Hospital · JPChiba Aoba Municipal Hospital · JPHiroshima University · JPJapanese Red Cross Society Kyoto Daini Hospital · JPSaga University · JPShinmatsudo Central General Hospital · JPEiju General Hospital · JPJuntendo University · JPJuntendo University Nerima Hospital · JPKansai Medical University · JPKobe City Nishi-Kobe Medical Center · JPKyoto first Red Cross hospital · JPKyoto Prefectural University of Medicine · JPKyoto University · JPNagano Red Cross Hospital · JPNTT Medical Center · JPOita University Hospital · JPPanasonic (Japan) · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleophosmin1 (NPM1) mutations are the most frequently detected gene mutations in acute myeloid leukemia (AML) and are considered a favorable prognostic factor. We retrospectively analyzed the prognosis of 605 Japanese patients with de novo AML, including 174 patients with NPM1-mutated AML. Although patients with NPM1-mutated AML showed a high remission rate, this was not a favorable prognostic factor for overall survival (OS); this is contrary to generally accepted guidelines. Comprehensive gene mutation analysis showed that mutations in codon R882 of DNA methyltransferase 3A (DNMT3A
Indexed as
DNA (Cytosine-5-)-MethyltransferasesLeukemia, Myeloid, AcuteDNA Methyltransferase 3ADNA Mutational AnalysisHumansMutationNucleophosminPrognosisRetrospective StudiesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanNPM1 protein, humanNucleophosminacute myeloid leukemiaDNMT3ANPM1prognostic factortriple mutation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.